High expression of the transcriptional coactivator TAZ is associated with a worse prognosis and affects cell proliferation in patients with medulloblastoma

  • Authors:
    • Hao Wang
    • Ji Zhou
    • Dong Yang
    • Liang Yi
    • Xuhui Wang
    • Yangqing Ou
    • Donghong Yang
    • Lunshan Xu
    • Minhui Xu
  • View Affiliations

  • Published online on: September 11, 2019     https://doi.org/10.3892/ol.2019.10851
  • Pages: 5591-5599
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The transcriptional coactivator tafazzin (TAZ) serves pivotal roles in organ development, tumor initiation and tumor progression. However, to the best of our knowledge, the expression of TAZ and its clinical significance in human medulloblastoma have not been defined. The present study aimed to clarify the clinical and biological significance of TAZ expression in human medulloblastoma. Immunohistochemical staining for TAZ was performed with 72 medulloblastoma and three normal brain tissue samples. A high expression level of TAZ was detected in 65.28% of medulloblastoma tissues, whereas low expression was identified in the normal brain tissues. TAZ expression was significantly associated with medulloblastoma recurrence. However, the expression of TAZ was not associated with sex, age, tumor location, tumor maximal diameter and tumor histology. Furthermore, both the overall survival and tumor‑free survival rate of patients with high levels of expression of TAZ were shorter compared with those of patients with tumors expressing low levels of TAZ. In univariate and multivariate Cox regression analyses, TAZ expression was identified as a significant prognostic factor for patients with medulloblastoma. Functionally, downregulation of TAZ inhibited the proliferation and tumor formation of medulloblastoma cells and the expression of cell‑cycle associated proteins in Daoy cells. In conclusion, high expression of TAZ may serve as a prognostic marker for patients with medulloblastoma and TAZ may be a potential target for medulloblastoma therapy.

Related Articles

Journal Cover

November 2019
Volume 18 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Wang, H., Zhou, J., Yang, D., Yi, L., Wang, X., Ou, Y. ... Xu, M. (2019). High expression of the transcriptional coactivator TAZ is associated with a worse prognosis and affects cell proliferation in patients with medulloblastoma. Oncology Letters, 18, 5591-5599. https://doi.org/10.3892/ol.2019.10851
MLA
Wang, H., Zhou, J., Yang, D., Yi, L., Wang, X., Ou, Y., Yang, D., Xu, L., Xu, M."High expression of the transcriptional coactivator TAZ is associated with a worse prognosis and affects cell proliferation in patients with medulloblastoma". Oncology Letters 18.5 (2019): 5591-5599.
Chicago
Wang, H., Zhou, J., Yang, D., Yi, L., Wang, X., Ou, Y., Yang, D., Xu, L., Xu, M."High expression of the transcriptional coactivator TAZ is associated with a worse prognosis and affects cell proliferation in patients with medulloblastoma". Oncology Letters 18, no. 5 (2019): 5591-5599. https://doi.org/10.3892/ol.2019.10851